Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic medical imaging, today announced the launch of its ultrasound contrast imaging agent, DEFINITY® Vial For (Perflutren Lipid Microsphere) Injectable Suspension, in India. The company has signed a multi-year agreement with Mumbai-based J.B. Chemicals & Pharmaceuticals, Ltd. ("JBCPL") for the distribution and marketing of DEFINITY® in the Indian marketplace. The launch expands Lantheus' presence in southern Asia. DEFINITY® is currently marketed in North America, Australia and New Zealand, parts of the Pacific Rim, and several countries in the Middle East.
“We are proud to partner with Lantheus Medical Imaging to launch DEFINITY® in India”
DEFINITY® is an ultrasound contrast imaging agent that is indicated in India for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border, as well as for use in patients in contrast-enhanced diagnostic ultrasound imaging to improve characterization of focal lesions of the liver and kidney.
"The introduction of DEFINITY® in India reinforces the important role this diagnostic imaging agent can play in helping physicians across the globe make informed decisions about patient treatment and care, " said Cyrille Villeneuve, Vice President and General Manager, International, at Lantheus Medical Imaging, Inc. "Accessing the Indian market is part of our global expansion strategy for DEFINITY®, and this agreement with JBCPL, a leading Indian supplier of pharmaceuticals and diagnostic imaging products, provides Lantheus with a great opportunity to sell product in this important geographic region. JBCPL has a strong marketing infrastructure and an extensive sales force, and we believe that they are the ideal partner to sell and distribute DEFINITY® in India."
"We are proud to partner with Lantheus Medical Imaging to launch DEFINITY® in India," said Mr. Pranabh Mody, President, J.B. Chemicals & Pharmaceuticals, Ltd. "DEFINITY® is a strategic fit for JBCPL and its addition to our product portfolio underscores our strength and continued commitment to the diagnostic medical imaging market."
New 3D body scan method beats traditional imaging for tracking body fat